109 related articles for article (PubMed ID: 37788594)
1. Oxymatrine inhibits melanoma development by modulating the immune microenvironment and targeting the MYC/PD-L1 pathway.
Li X; He L; Ou Y; Wang S; Hu Y; Niu H
Int Immunopharmacol; 2023 Nov; 124(Pt B):111000. PubMed ID: 37788594
[TBL] [Abstract][Full Text] [Related]
2. The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun.
Yu P; Wei H; Li K; Zhu S; Li J; Chen C; Zhang D; Li Y; Zhu L; Yi X; Liu N; Liu P; Zhao S; Chen X; Peng C
J Exp Clin Cancer Res; 2022 Dec; 41(1):346. PubMed ID: 36522774
[TBL] [Abstract][Full Text] [Related]
3. Oxymatrine reduces expression of programmed death-ligand 1 by promoting DNA demethylation in colorectal cancer cells.
Hua S; Gu M; Wang Y; Ban D; Ji H
Clin Transl Oncol; 2021 Apr; 23(4):750-756. PubMed ID: 32737836
[TBL] [Abstract][Full Text] [Related]
4. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
5. Galangin inhibits programmed cell death-ligand 1 expression by suppressing STAT3 and MYC and enhances T cell tumor-killing activity.
Zhong Y; Li MY; Han L; Tai Y; Cao S; Li J; Zhao H; Wang R; Lv B; Shan Z; Zuo HX; Piao L; Jin HL; Xing Y; Jin X; Ma J
Phytomedicine; 2023 Jul; 116():154877. PubMed ID: 37267692
[TBL] [Abstract][Full Text] [Related]
6. Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy.
Zhang W; He Z; Liang F; Gong J; Tan L; Yang J; Song S; Xie L; Lu Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16763-16778. PubMed ID: 37730912
[TBL] [Abstract][Full Text] [Related]
7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
8. Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression.
Barnwal A; Tamang R; Sanjeev Das ; Bhattacharyya J
Br J Cancer; 2023 Oct; 129(6):1007-1021. PubMed ID: 37400678
[TBL] [Abstract][Full Text] [Related]
9. Silencing of Perilipin 3 Inhibits Lung Adenocarcinoma Cell Immune Resistance by Regulating the Transcription of PD-L1 Through c-Myc.
Men X; Zhu W
Immunol Invest; 2023 Nov; 52(7):815-831. PubMed ID: 37578465
[TBL] [Abstract][Full Text] [Related]
10. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
11. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
12. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
13. Formononetin represses cervical tumorigenesis by interfering with the activation of PD-L1 through MYC and STAT3 downregulation.
Wang JY; Jiang MW; Li MY; Zhang ZH; Xing Y; Ri M; Jin CH; Xu GH; Piao LX; Jin HL; Ma J; Jin Y; Zuo HX; Jin X
J Nutr Biochem; 2022 Feb; 100():108899. PubMed ID: 34748924
[TBL] [Abstract][Full Text] [Related]
14. An Immunomodulatory Gallotanin-Rich Fraction From
Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S
Front Immunol; 2020; 11():584959. PubMed ID: 33312174
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus-triggered PTEN/β-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion.
Sun Y; Yu M; Qu M; Ma Y; Zheng D; Yue Y; Guo S; Tang L; Li G; Zheng W; Wang M; Guo D; Li C
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G162-G173. PubMed ID: 31604033
[TBL] [Abstract][Full Text] [Related]
17. 2-methoxyestradiol inhibits melanoma cell growth by activating adaptive immunity.
Hua W; Huang X; Li J; Feng W; Sun Y; Guo C
Immunopharmacol Immunotoxicol; 2022 Aug; 44(4):541-547. PubMed ID: 35451929
[No Abstract] [Full Text] [Related]
18. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
[TBL] [Abstract][Full Text] [Related]
19. ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma.
Qu T; Zhang W; Yan C; Ren D; Wang Y; Guo Y; Guo Q; Wang J; Liu L; Han L; Li L; Huang Q; Cao L; Ye Z; Zhang B; Zhao Q; Cao W
J Transl Med; 2023 May; 21(1):341. PubMed ID: 37217923
[TBL] [Abstract][Full Text] [Related]
20. Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.
Taube JM; Young GD; McMiller TL; Chen S; Salas JT; Pritchard TS; Xu H; Meeker AK; Fan J; Cheadle C; Berger AE; Pardoll DM; Topalian SL
Clin Cancer Res; 2015 Sep; 21(17):3969-76. PubMed ID: 25944800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
